Beijing Tiantan Biological Products (600161CH)-A Good Defensive Investment Target but May Overvalued

279 Views30 Nov 2022 08:34
Tiantan is a good defensive target in unfriendly external macro due to its advantageous background, but performance growth would slow down in 2022. The current valuation may have overdrawn certainty.
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
(Paid Plans Only)